» Articles » PMID: 32206858

Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?

Overview
Journal Lung
Specialty Pulmonary Medicine
Date 2020 Mar 25
PMID 32206858
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Pulmonary hypertension (PH) is a well-recognised complication of interstitial lung diseases (ILD), which worsens prognosis and impairs exercise capacity. Echocardiography is the most widely used, non-invasive method for PH assessment. The aim of our study was to identify the factors predictive for echocardiographic signs of PH in newly recognised ILD patients.

Methods: Ninety-three consecutive patients (28F/65M) with different ILD were prospectively evaluated from January 2009 to March 2014. Pulmonary function testing, 6-min walk distance (6MWD), initial and sixth minute room air oxygen saturation, NT-proBNP and echocardiography were assessed in each patient. Echocardiographic PH probability was determined according to the 2009 ESC/ERS guidelines.

Results: In 41 patients (Group B) increased PH possibility has been diagnosed on echocardiography, in 52 patients (Group A)-low PH probability. Most pronounced differences (p ≤ 0.0005) between groups B and A concerned: age, 6MWD, room air oxygen saturation at 6 min, DLCO and TLC/DLCO index (57.6 vs 43.8 years; 478 vs 583 m; 89.1% vs 93.4%; 54.8% predicted vs 70.5% predicted and 1.86 vs 1.44; respectively). Univariate analysis showed four-fold increased probability of PH when TLC/DLCO exceeded 1.67. A scoring system incorporating age, TLC/DLCO index, 6MWD and room air oxygen saturation at 6 min provided high diagnostic utility, AUC 0.867 (95% CI 0.792-0.867).

Conclusion: ILD patients with TLC/DLCO index > 1.67 have a high likelihood of PH and should undergo further evaluation. The composite model of PH prediction, including age, 6-min walk test and TLC/DLCO was highly specific for recognition of PH on echocardiography.

Citing Articles

Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease.

Kim H, Chandel A, King C, Kim M, Shawabkeh M, Arunachalam A Lung. 2025; 203(1):27.

PMID: 39841267 PMC: 11754375. DOI: 10.1007/s00408-024-00783-2.


Screening and diagnosis of pulmonary hypertension associated with chronic lung disease (PH-CLD): A consensus statement from the pulmonary vascular research institute's innovative drug development initiative-group 3 pulmonary hypertension.

Vitulo P, Piccari L, Wort S, Shlobin O, Kovacs G, Vizza C Pulm Circ. 2024; 14(4):e70005.

PMID: 39659477 PMC: 11629413. DOI: 10.1002/pul2.70005.


Noninvasive diagnostic modalities and prediction models for detecting pulmonary hypertension associated with interstitial lung disease: a narrative review.

Arvanitaki A, Diller G, Gatzoulis M, McCabe C, Price L, Wort S Eur Respir Rev. 2024; 33(174).

PMID: 39384306 PMC: 11462299. DOI: 10.1183/16000617.0092-2024.


Pulmonary hypertension associated with lung diseases.

Shlobin O, Adir Y, Barbera J, Cottin V, Harari S, Jutant E Eur Respir J. 2024; 64(4).

PMID: 39209469 PMC: 11525344. DOI: 10.1183/13993003.01200-2024.


Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future.

Arslan A, Smith J, Qureshi M, Uysal A, Patel K, Herazo-Maya J Front Med (Lausanne). 2024; 10:1306032.

PMID: 38298504 PMC: 10827954. DOI: 10.3389/fmed.2023.1306032.


References
1.
Nathan S, Barbera J, Gaine S, Harari S, Martinez F, Olschewski H . Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2018; 53(1). PMC: 6351338. DOI: 10.1183/13993003.01914-2018. View

2.
Szturmowicz M, Kacprzak A, Blasinska-Przerwa K, Kus J . Pulmonary hypertension in the course of diffuse parenchymal lung diseases - state of art and future considerations. Pneumonol Alergol Pol. 2015; 83(4):312-23. DOI: 10.5603/PiAP.2015.0051. View

3.
. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by.... Am J Respir Crit Care Med. 1999; 160(2):736-55. DOI: 10.1164/ajrccm.160.2.ats4-99. View

4.
Pellegrino R, Viegi G, Brusasco V, Crapo R, Burgos F, Casaburi R . Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5):948-68. DOI: 10.1183/09031936.05.00035205. View

5.
Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Respir J. 2015; 46(4):903-75. DOI: 10.1183/13993003.01032-2015. View